Tonix Pharmaceuticals

Receive alerts
Market Cap:
$238.3 m
0.91 USD
52 weeks high
52 weeks low

In brief

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions. Tonix’s lead product candidate, TNX-102 SL*, is in development for posttraumatic stress disorder (PTSD), fibromyalgia, agitation in Alzheimer’s disease (AAD) and alcohol use disorder (AUD). TNX-102 SL is in Phase 3 development as a bedtime treatment for PTSD and fibromyalgia. The AAD program is Phase 2 ready and the development for AUD is in the pre-IND application stage. Tonix is also developing TNX-601 CR as a daytime treatment for PTSD, as well as for depression. It is Phase 2-ready for a depression study, ex-U.S, and is expected to be IND-ready in the U.S. this year. Finally, Tonix also has a robust pipeline of preclinical products as well as biodefense programs.

*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Upcoming Proactive virtual event brings together a quartet of innovative companies across industries

The four companies this week are plant-centric technology firm Calyxt, online gaming company Esports Entertainment, IT and HR acquisition firm HIRE Technologies, and biopharmaceutical company...

on 17/8/20